Search
Blueprint Medicines Corp
BPMCAdd to Watchlist
129.460USD
0.0000.00%
Market hours （ET）Quotes delayed by 15 min
8.36BMarket Cap
LossP/E TTM
More Details of Blueprint Medicines Corp Company
Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.
Blueprint Medicines Corp Info
Ticker SymbolBPMC
Company nameBlueprint Medicines Corp
IPO dateApr 30, 2015
CEOMs. Kathryn D (Kate) Haviland
Number of employees649
Security typeOrdinary Share
Fiscal year-endApr 30
Address45 Sidney Street
CityCAMBRIDGE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02139
Phone16173747580
Websitehttps://www.blueprintmedicines.com/
Ticker SymbolBPMC
IPO dateApr 30, 2015
CEOMs. Kathryn D (Kate) Haviland
Company Executives of Blueprint Medicines Corp
Name
Name/Position
Position
Shareholding
Change
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer
President, Chief Executive Officer
73.23K
+0.03%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+0.10%
Ms. Christina Rossi
Ms. Christina Rossi
Chief Operating Officer
Chief Operating Officer
19.39K
-0.10%
Mr. Percy H. Carter, Ph.D.
Mr. Percy H. Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
16.43K
-0.08%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
13.43K
-0.51%
Ms. Ariel Hurley, CPA
Ms. Ariel Hurley, CPA
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
11.89K
--
Mr. Michael J. Tolpa
Mr. Michael J. Tolpa
Director
Director
--
--
Ms. Debra Durso-Bumpus
Ms. Debra Durso-Bumpus
Chief People Officer
Chief People Officer
--
--
Dr. Philina Lee, Ph.D.
Dr. Philina Lee, Ph.D.
Chief Commercial Officer
Chief Commercial Officer
--
-100.00%
Ms. Jenna Cohen
Ms. Jenna Cohen
Vice President and Head, Investor Relations
Vice President and Head, Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer
President, Chief Executive Officer
73.23K
+0.03%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+0.10%
Ms. Christina Rossi
Ms. Christina Rossi
Chief Operating Officer
Chief Operating Officer
19.39K
-0.10%
Mr. Percy H. Carter, Ph.D.
Mr. Percy H. Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
16.43K
-0.08%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
13.43K
-0.51%
Ms. Ariel Hurley, CPA
Ms. Ariel Hurley, CPA
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
11.89K
--
FAQs
Who are the top five shareholders of Blueprint Medicines Corp?
The top five shareholders of Blueprint Medicines Corp are: Ms. Kathryn D (Kate) Haviland
How many institutions hold shares of Blueprint Medicines Corp (BPMC)?
As of 2025Q2, 701 institutions hold shares of Blueprint Medicines Corp, with a combined market value of approximately 68.81M, accounting for 106.41% of the total shares. Compared to 2025Q1, institutional shareholding has increased by -3220329.00.
What is the biggest source of revenue for Blueprint Medicines Corp?
In 2025Q2, the Product revenue business generated the highest revenue for Blueprint Medicines Corp, amounting to 128.18M and accounting for 100.00% of total revenue.
